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Case Report
A 44-year-old woman with a history of triple-negative breast
cancer metastatic to the brain presented with changes in mental
status, lower back pain, and a left facial Bell’s palsy.
The patient had previously been ambulatory and fully cognizant
of her surroundings until one week prior to presentation when
she began to exhibit progressively worsening confusion. As her
mental status began to change, the patient developed new onset
pain over her lumbar spine, supra-pubic area, bilateral flanks,
hips, and knees. The pain was refractory to an epidural injection
into her lumbar spine performed at the patient’s local hospital.
Other complaints included a recent onset urinary retention,
weakness of the left lower extremity, a left facial Bell’s palsy,
and difficulty walking. On admission, the patient was taking
gabapentin, citalopram, aspirin, enoxaparin, nystatin, lopressor,
docusate, lorazepam, and methylprednisone. The patient was
treating her pain with hydromorphone hydrochloride as needed.
No other medications had recently been prescribed.
Past medical history included breast cancer status post bilateral
mastectomies, four cycles of chemotherapy with paclitaxel,
and neo-adjuvant radiation. One month prior to presentation,
the patient was found to have metastases to her brain, and
underwent a left fronto-temporal craniotomy that was then
followed by a course of whole brain irradiation.
Upon examination, the patient was confused and had difficulty
speaking and swallowing. Her temperature was 97.4˚F, her pulse
was 95 beats per minute, her respiratory rate was 20 breaths
per minute, and her blood pressure was 143/88 mm Hg. The
patient’s pulse oximetry on room air was 95%. Her pupils were
anicteric and equally round and reactive to light, but a left visual
field defect was noted. The patient exhibited facial nerve palsy
involving the entire left side of the face. All other cranial nerves
appeared intact. The patient showed diffuse myoclonic jerks in
her upper extremities. Motor testing revealed 3/5 strength in the
left leg and 4/5 strength in the right leg. Sensation was preserved
throughout the extremities. The patient’s cardiac exam was
normal, and her lungs were clear to auscultation bilaterally.
Her abdomen was soft and non-distended, and her legs were
non-edematous.
The patient’s white blood cell count was 6300 cells/mm3 with
a differential of 76.3% neutrophils and 11.9% lymphocytes.
Hemoglobin was 13.5 g/dL, hematocrit was 40.4%, and platelets
were 229,000/ml. Electrolyte values and coagulation tests were
both within normal limits. The patient’s ESR was elevated at
60. Her liver function tests showed a total protein of 6.9 gm/
dl, albumin of 4.2 gm/dl, total bilirubin 1.4 mg/dl, direct
bilirubin 0.6 mg/dl, AST of 33 U/L, ALT 32 U/L, and alkaline
phosphatase of 82 U/L. Blood and urine cultures were negative
for bacterial growth.

A CT scan of the patient’s spine revealed mild multilevel
degenerative changes with no evidence of lytic or blastic lesions.
An MRI of the spine showed no evidence of bony metastases,
spinal cord compression, or significant spinal stenosis, and a
long bone scan was also negative for any bone lesions. A head
CT scan was negative for intracranial hemorrhage, mass effects,
vasogenic edema or midline drift. A brain MRI was notable for
thick nonspecific dural enhancement along the left anterior
frontal convexity.
After admission, the patient’s mental status continued to rapidly
decline. A lumbar puncture was performed and cerebrospinal
fluid analysis revealed low glucose of 13 mg/dl, increased protein
of 256 mg/dl, chloride of 115 mg/dl, and a pH of 7.97. Red cell
count was 155 cells/µl, and white cell count was 14 cells/µl,
with a differential of 14% neutrophils and 68% lymphocytes.
A cryptococcal antigen test of the CSF fluid was nonreactive
and cytology results of the CSF fluid were non-diagnostic. The
clinical picture was suggestive of a diagnosis of leptomeningeal
carcinomatosis.
Neuro-oncology was consulted regarding the patient’s potential
for intrathecal chemotherapy treatment. Unfortunately, her
condition was deteriorating so rapidly that the family opted
for palliative care management, and the patient expired soon
afterwards in the hospital.

Discussion
Carcinomatosis is a condition in which cancer spreads diffusely
throughout the body, and can take place in both the peritoneum
and the leptomeninges. Leptomeningeal carcinomatosis (LC),
also known as neoplastic meningitis, occurs when a patient’s
cancer metastasizes to the meninges surrounding the spinal
cord and spreads diffusely throughout the subarachnoid space
to produce multifocal neurological signs and symptoms. It is an
end-stage cancer phenomenon, and a relatively rare metastasis.
Malignant cells can metastasize to the meninges in several ways.
Hematogenous spread is the most common route, but this type
of entry is more often seen in hematologic malignancies like
leukemia than in solid primary cancers. Solid tumors tend to
spread through lymphatics to reach the meninges, and enter the
subarachnoid space by passing through the dural and arachnoid
coverings of spinal and cranial nerve roots. Other pathways
described include direct spread from metastases in the CNS
parenchyma, as well as iatrogenic spread through an accidental
ependymal or dural breach created by a neurosurgical procedure.
No matter the route, once malignant cells gain access to the CSF,
they seed the meningeal surface by CSF flow and grow to form
deposits that can appear either diffusely thin, or plaque-like and
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forming nodules along the meninges. The cancerous cells can
then invade the pial membrane to reach the spinal nerves, cranial
nerves, and spinal cord, resulting in the multifocal neurologic
symptoms that characterize the metastasis.
LC is diagnosed clinically in 5-8% of solid tumor cancer patients
and in 5-15% of patients with leukemia/lymphoma. However,
autopsy results of cancer patients who showed neurological signs
and symptoms prior to death have revealed undiagnosed LC in
20% of cases.1 This can be explained by the fact that LC is usually
an end-stage complication of metastatic cancer; confusion and
pain are common in terminal cancer patients, so many cases
of symptomatic LC may be overlooked in the late stages of
metastatic cancer.2
The most common causes of LC are breast and lung cancer,
even though other rare malignancies may be more inclined to
metastasize to the meninges; this is because breast cancer patients
have a longer life expectancy and a larger patient population.
Incidences of LC in different cancer populations are as follows:
melanoma >23%, small cell lung cancer 6-25%, leukemias 10%,
lymphomas 7%, breast cancer 2-5%, and non-small cell lung
cancers 1-5%.3
It has been noted recently that the incidence of LC has been
increasing in both the breast and lung cancer populations.2
This phenomenon can be explained by several causes. Ongoing
improvements in cancer treatment have led to better systemic
control of cancer and longer patient survival time, which allows
for LC to occur in the end stages of the disease. In addition, many
popular chemotherapeutic drugs will not cross the blood-CSF
barrier; thus, while the patient is being treated systemically, any
subarachnoid tumor cells present are not adequately treated
and can still proliferate. Two examples of such chemotherapeutic agents are taxanes and trastuzumab, both of which are
commonly utilized in breast and lung cancer. Finally, there is
an increased rate of clinical diagnosis of LC due to heightened
physician awareness and neuro-imaging studies that can help to
confirm the suspicion.2
Multifocal neurological symptoms are the classic presentation
of LC, but clinical signs can be absent in at least 25% of patients
at time of diagnosis. 1 Patients most commonly complain of
headache, change in mental status, confusion, facial and auditory
deficits, diplopia, back pain, and lower extremity numbness
or weakness. 15% of patients will show signs and symptoms
associated with cerebral hemispheric dysfunction (headache,
dizziness, nausea/vomiting), 35% of patients will show signs and
symptoms associated with cranial nerves (diplopia, facial nerve
palsies), and 60% of patients will show signs and symptoms
associated with the spinal cord and nerve roots (radicular pain
or weakness, urinary incontinence or retention).1
Early diagnosis of LC is essential to prevent further complications
and neurological damage, and so all patients suspected of
having the disease should receive a lumbar puncture and an
MRI of the spinal cord. Classic CSF findings in LC include
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elevated protein concentration, lymphocytic pleocytosis, and
decreased glucose concentration, which were all seen in our
patient. MRI findings suggestive of LC include cranial nerve,
subependymal, and leptomeningeal enhancement. While CSF
cytology with evidence of malignant cells remains the gold
standard for diagnosis, cytology results are positive upon first
lumbar puncture in only 54% of LC patients, and may remain
falsely negaive in up to 14% of LC patients after even three CSF
samplings.4 Cytology is more likely to prove the existence of LC
when meningeal involvement is diffuse or when the sampling
site is closer to the site of the main focus of metastasis. Even
if cytology of the CSF is non-diagnostic, and there exists an
opening pressure above 15 cm H2O, an elevated white blood
cell count, a protein concentration greater than 50 mg/dL, or a
glucose concentration less than 60 mg/dL, LC remains a likely
cause of the patient’s symptoms.3 Therefore, in advanced cancer
patients with multifocal neurological symptoms, typical MRI
image findings, and suggestive CSF fluid analysis, the diagnosis
of leptomeningeal carcinomatosis is quite straightforward.2
Treatment of leptomeningeal carcinomatosis requires a multidisciplinary approach. The current goal of therapy is improvement
or stabilization of patients’ neurologic symptoms. Therapeutic
approaches include intrathecal chemotherapy (mainly with
methotrexate), radiotherapy of the meninges, systemic
chemotherapy with drugs that penetrate the CSF, and surgery
to relieve increased intracranial pressure.5 A recent study has
shown that systemic chemotherapy, intrathecal chemotherapy,
and whole brain radiation all have a positive impact on
patient survival, while radiotherapy of the spinal meninges
does not influence patient survival time. While radiotherapy
and intrathecal chemotherapy were once the mainstays of LC
treatment, systemic chemotherapy (utilizing drugs that can
penetrate the subarachnoid space) is gaining popularity as a
therapeutic option, as it treats both the meningeal carcinomatosis as well as the systemic malignancy. Recent recommendations for the treatment of LC suggest focal radiation first to
debulk any tumors, followed by a course of chemotherapy. Solid
tumors have a propensity to attach to neural structures in the
form of bulky nodules, while hematologic malignancies tend to
spread more diffusely along the meninges. The leptomeningeal
nodules caused by the spread of solid tumors are more likely to
show up as areas of enhancement on MRI. Intravenous systemic
chemotherapy is preferred in patients who have multiple
nodules or MRI evidence of leptomeningeal enhancement, and
intrathecal chemotherapy is preferred in patients with positive
CSF cytology but negative MRI scans.5
Aggressive treatment is unlikely to improve neurologic
symptoms in many patients; indeed, neurologic toxicity can
result, instead. In these patients, palliation may be the best
option. If left untreated, the median survival time of LC
patients is 3-6 weeks. With treatment, median survival time is
variable, ranging from 7-16.5 weeks depending on the patient’s
performance status and primary tumor site.3 Of the LC patients
who die, 24-34% die from progression of the leptomeningeal
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carcinomatosis itself, 22-25% die from progression of both LC
and the systemic disease, and 19-44% die from progression
of the systemic cancer alone.3 Several prognostic factors have
been indicated in response to treatment, including age, tumor
type, and neurological status at time of diagnosis. A series of
studies of LC patients demonstrated that 61% of breast cancer
patients showed a neurological stabilization or advancement
with radiation and chemotherapy, while only 39% of lung
carcinoma and 18% of melanoma patients achieved similar
results. Patients with breast cancer as their primary malignancy
have been shown to have the best prognosis of all patients with
leptomeningeal metastases, and are consequently most likely to
benefit from aggressive treatment.2
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